<DOC>
	<DOCNO>NCT00939198</DOCNO>
	<brief_summary>Na-ASP-2 protein express larval stage N. americanus hookworm life cycle . In clinical study previously hookworm-infected adult Brazil , protein induce urticarial reaction ( rash ) subset volunteer . The clinical trial component study involve skin test immediate-type hypersensitivity Na-ASP-2 Antigen . Both prick-puncture intradermal test apply .</brief_summary>
	<brief_title>Prevalence Hookworm Infection Community Preparedness Hookworm Vaccine Trials Endemic Areas Brazil</brief_title>
	<detailed_description>The clinical test Na-ASP-2 Skin Test Reagent detect Immediate-type hypersensitivity Na-ASP-2 hookworm antigen conduct part large , on-going observational study prevalence intensity hookworm infection currently underway Brazil . Eligible adult participant ( age 18-45 year ) observational study invite undergo skin test procedure . Skin test perform agree sign supplemental inform consent form skin test procedure . - Study site : Americaninhas Vaccine Center , Americaninhas , Minas Gerais , Brazil - Number participant skin test : approximately 150 adult - Duration skin test procedure : 1 month ; participant undergo skin test follow-up blood collection 21+/-7 day skin test . - Each participant skin prick-puncture intradermal skin test apply study day . The prick-puncture intradermal test apply sequentially volar aspect participant 's forearm : 1 . Skin prick-puncture : three different concentration Na-ASP-2 solution ( 10 , 100 , 1000 μg/mL ) apply sequentially duplicate , leave forearm . 2 . Intradermal : one concentration Na-ASP-2 ( 100 μg/mL ) inject , duplicate , right forearm . 3 . Allergen diluent histamine solution utilized negative positive control , respectively , skin prick-puncture intradermal test . 4 . Participants observe study clinic least 30 minute follow application skin test , examine 2 7 day follow skin test . 5 . Sizes wheal erythema reaction application record graded comparison histamine positive control reaction . - Each participant blood collect via venipuncture ( maximum 25 mL ) immediately prior application skin test , 2 4 week skin testing , order measure antibody ( particularly IgG IgE ) Na-ASP-2 use ELISA procedure .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 6 45 year age , inclusive , time consent parent study . Age great equal 18 year time sign supplemental informed consent document skin test procedure ( parent study ) . Willingness participate study evidence sign informed consent assent document . Inability correctly answer question inform consent comprehension questionnaire . Attends school work fulltime outside study area . Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate study protocol . Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Pregnancy determine positive urine hCG test ( female ) . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day plan skin test application . Extensive dermatitis preclude skin testing . Current use beta blocker ( oral topical ) antihistamine medication . A volunteer may participate study agree withhold use antihistamine least 5 day prior application skin test . Use tricyclic antidepressant within past month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hookworm</keyword>
	<keyword>Allergy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Skin Test</keyword>
	<keyword>Immediate-type hypersensitivity Na-ASP-2 hookworm antigen</keyword>
</DOC>